Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

Supportive Care in Cancer

Volumn 17, Issue 5, 2009, Pages 589-594

  Grunberg, Steven M ^a   Dugan, Matthew ^b   Muss, Hyman ^a   Wood, Marie ^a   Burdette Radoux, Susan ^a   Weisberg, Tracey ^b   Siebel, Marisa ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Maine Center for Cancer Medicine and Blood Disorders   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Antiemetic; Aprepitant; Dexamethasone; Palonosetron

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PALONOSETRON; TRASTUZUMAB; TRIPTORELIN;

ACUTE DISEASE; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; QUINUCLIDINES; TIME FACTORS; VOMITING;

EID: 64449084071     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0535-9     Document Type: Article

References (36)

1. ASHP 1999 ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery Am J Health Syst Pharm 56 729 764
2. TM Beck PH Hesketh S Madajewicz 1992 Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting J Clin Oncol 10 1969 1975
3. RA Blum A Majumdar J McCrea 2003 Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 1407 1419
4. SP Chawla SM Grunberg RJ Gralla 2003 Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97 2290 2300
5. V Cocquyt S Van Belle RR Reinhardt 2001 Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis Eur J Cancer 37 835 842
6. L Cohen CA de Moor P Eisenberg 2007 Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings Support Care Cancer 15 497 503
7. C De Jongh Garcia S Poli C Ananth 2005 Health care provider perception of nausea and vomiting and patients' reported incidence: the Venezuela Emesis Registry Support Care Cancer 13 414 415
8. R De Wit 2003 Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics Br J Cancer 88 182 187
9. P Eisenberg J Figueroa-Vadillo R Zamora 2003 Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 1473 1482
10. A Erazo Valle T Wisniewski JI Figueroa Vadillo 2006 Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed Curr Med Res Opin 22 2403 2410
11. DS Ettinger PJ Bierman B Bradbury 2007 Antiemesis J Natl Compr Canc Netw 5 12 33
12. R Gralla M Lichinitser S Van Der Vegt 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577
13. AM Griffin PN Butow AS Coates 1996 On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 7 189 195
14. T Grote J Hajdenberg A Cartmell 2006 Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant J Support Oncol 4 403 408
15. SM Grunberg RR Deuson P Mavros 2004 Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261 2268
16. S Grunberg DS Ettinger AB Hauber 2008 How familiar are oncologists with therapeutic care and supportive care guidelines? Support Care Cancer 16 631 632
17. JD Herrington AD Jaskiewicz J Song 2008 Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting Cancer 112 2080 2087
18. PJ Hesketh SM Grunberg RJ Gralla 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112 4119
19. KJ Horgan K Petty A Majumdar 2003 Treatment options for chemotherapy-induced nausea and vomiting: current and future Am J Cancer 2 391 392
20. S Kripalani M Price V Vigil 2008 Frequency and predictors of prescription-related issues after hospital discharge J Hosp Med 3 12 19
21. MG Kris RJ Gralla RA Clark 1988 Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy J Clin Oncol 6 659 662
22. MG Kris PJ Hesketh MR Somerfield 2006 American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932 2947
23. CT Liau NM Chiu HE Liu 2005 Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes Support Care Cancer 13 277 286
24. WJ Loos R de Wit SJ Freedman 2007 Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients Cancer Chemother Pharmacol 59 407 412
25. E Maranzano PC Feyer A Molassiotis 2005 Evidence-based recommendations for the use of antiemetics in radiotherapy Radiother Oncol 76 227 233
26. JB McCrea AK Majumdar MR Goldberg 2003 Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone Clin Pharmacol Ther 74 17 24
27. AC Modi DA Morita TA Glauser 2008 One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur Pediatrics 121 e961 e966
28. RM Navari RR Reinhardt RJ Gralla 1999 Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group N Engl J Med 340 190 195
29. P Nygren K Hande KJ Petty 2005 Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients Cancer Chemother Pharmacol 55 609 616
30. AH Partridge A LaFountain E Mayer 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556 562
31. S Poli-Bigelli J Rodrigues-Pereira AD Carides 2003 Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 3090 3098
32. C Sandoval D Corbi B Strobino 1999 Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naïve pediatric oncology patients Cancer Invest 17 309 313
33. AK Shah TL Hunt SC Gallagher 2005 Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers Curr Med Res Opin 21 595 601
34. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10
35. DG Warr PJ Hesketh RJ Gralla 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830
36. JR Wu DK Moser TA Lennie 2008 Medication adherence in patients who have heart failure: a review of the literature Nurs Clin North Am 43 133 153